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Abstract
Rheumatoid arthritis (RA) is a prevalent and debilitating autoimmune disease that affects the joints. RA is characterized
by an infiltration of the affected joint by blood-derived cells. In response to activation, these cells generate reactive oxygen
species, resulting in an oxidative stress situation. One approach to counteract this oxidative stress situation is the use of
antioxidants as therapeutic agents. The free radical scavenger enzyme superoxide dismutase (SOD) may be used as a
therapeutic agent in rheumatoid arthritis, but its rapid elimination from the circulation is a major limitation. Targeted
delivery of SOD may overcome this limitation. In this study, the utility of PEGylated liposomes (PEG-liposomes) for
targeting SOD to arthritic sites was explored. The targeting of SOD to arthritic sites following intravenous administration of
both PEG-liposomes and positively charged liposomes lacking PEG but containing stearylamine (SA-liposomes) in rats with
adjuvant arthritis was studied. At 24 h post injection, the blood levels of long circulating liposomes with a mean size of
0.11 Wm and 0.20 Wm were 8- and 3-fold higher, respectively, as compared to the SA-liposomes. The majority of SOD
administered in liposomal form remains within the liposomes when they circulate in the bloodstream. The highest target
uptake was observed with PEG-liposomes with a mean size of 0.11 Wm and the lowest uptake with the SA-liposomes. These
results demonstrate that SOD can be targeted to inflamed sites most efficiently via small-sized PEG-liposomes. Small-sized
PEG-coated liposomes are to be preferred if prolonged circulation and enhanced localization of SOD at arthritic sites are
desired. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Rheumatoid arthritis, an autoimmune in£amma-
tory disease of unknown origin, is the most common
disease of connective tissues [1^3]. Since a cure for
this disease with unknown etiology is not available
[1,4], there is still an urgent need for a therapeutic
agent capable of preventing disease progression or
reversing joint destruction.
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Rheumatoid arthritis is characterized by an in¢l-
tration of the a¡ected articulations by blood-derived
cells, mainly neutrophils [5], macrophages and den-
dritic cells [6]. In response to activation, these cells
are responsible for the generation of reactive oxygen
species (ROS) [6,7], which are released in vast
amounts into the surrounding tissue. If the endoge-
nous antioxidant defense is overcome, the resulting
oxidative stress can induce destruction of the a¡ected
joint constituents such as synovial £uid, cartilages
and lipids [7]. One approach to decrease the oxida-
tive stress is the use of antioxidants as therapeutic
agents [8^11]. The most abundant ROS produced
during the in£ammatory process is the superoxide
radical [7]. Given the important role of the super-
oxide radical there is a major interest in the free
radical scavenger enzyme superoxide dismutase
(SOD) as a therapeutic agent in rheumatoid arthritis.
However, a major limitation of the therapeutic use of
SOD is its rapid elimination from the circulation via
the kidneys, with a plasma half-life of 6 min [12,13].
In order to improve its therapeutic activity attempts
have been made to prolong the half-life of SOD. For
example, it has been covalently conjugated to poly-
(ethyleneglycol) (PEG) [14], dextran and albumin
[15]. Another approach to increase blood half-life is
the incorporation of SOD in liposomes [16,17]. Re-
cently we reported pharmacokinetic studies indicat-
ing that liposomal encapsulation of the enzyme in-
creased the plasma terminal half-life of the enzyme
after i.v. administration 5^10-fold (depending on lip-
osome type used) [18]. The SOD-liposome formula-
tions tested induced a reduction of arthritis indices in
a rat model of adjuvant arthritis. In particular, pos-
itively charged liposomes containing stearylamine
(SA) appeared to be promising in this regard.
At present, a leading liposome-based strategy to
target therapeutic agents to sites of pathology like
tumors and sites of infection and in£ammation is
to utilize liposomes with prolonged circulation times
[19^21]. Most popular in this regard is the inclusion
of PEG linked to the phospholipid distearoylphos-
phatidylethanolamine. Such PEG-liposomes are re-
ferred to as long circulating liposomes (LCL), steri-
cally stabilized liposomes or Stealth liposomes
[22,23]. The addition of PEG to the surface of the
liposomes gives the liposomes a hydrophilic ‘steri-
cally stabilized’ surface, a property that contributes
to a lower a⁄nity of macrophages of the mononu-
clear phagocyte system (MPS) for the circulating lip-
osome particles and consequently to a prolonged
blood circulation [19^21]. In a variety of experimen-
tal models, these long-circulating PEG-liposomes
have been shown to localize preferentially at sites
of infection and in£ammation [13,23^25], provided
that they are relatively small in size (6 150 nm).
The crucial aspect behind this bene¢cial phenomenon
is that the prolonged residence time in the blood
enables the PEG-liposomes to extravasate to a rela-
tively high degree at sites of enhanced vascular per-
meability [26^28].
The valuable property of PEG-liposomes to local-
ize preferentially at sites characterized by an in-
creased capillary permeability may be exploited to
further improve the application of liposomes as car-
riers of SOD. In this study, we compared the utility
of PEG-liposomes for targeting SOD to arthritic sites
with that of the previously used non-PEG-liposomes
containing SA in rats with adjuvant arthritis. The
results demonstrate that PEG-liposomes are superior
with respect to circulation time and extent of local-
ization at arthritic sites.
2. Materials and methods
2.1. Chemicals
Egg phosphatidylcholine (E-PC) was obtained
from Lipoid (Ludwigshafen, Germany). Distearoyl-
phosphatidylethanolamine-poly(ethyleneglycol) 2000
(PEG-DSPE) was obtained from Avanti Polar Lipids
(Alabaster, AL, USA). Cholesterol (Chol), SA, dieth-
ylenetriaminepentaacetic acid (DTPA) and bovine
erythrocyte Cu-Zn SOD were purchased from
Sigma (St. Louis, MO, USA). 111In-8-Hydroxy-
quinoline (111In-oxine) was obtained from Mallinck-
rodt (Petten, The Netherlands). Na131I was pur-
chased from Medgenix (Fleurus, Belgium; spec.
act. s 5 mCi/mg). 1,3,4,6-Tetrachloro-3K,6K-diphen-
ylglucouril was from Pierce (Rockford, IL, USA).
All other chemicals were of reagent grade.
2.2. Animals
Male Wistar rats older than 2.5 months and
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weighing 200^250 g were obtained from the Central
Animal Facility of the Medical Faculty of the Uni-
versity of Nijmegen, The Netherlands. Animals were
fed with standard laboratory food and water ad libi-
tum.
2.3. Synthesis of 131I-SOD
SOD was radiolabeled using the Iodogen method
[29]. Brie£y, 300 Wg SOD (10 Wg/Wl) and 10 Wl 0.5 M
phosphate bu¡er, pH 7.4 were mixed with 5 mCi
Na131I in a glass vial, precoated with 25 Wg 1,3,4,6-
tetrachloro-3K,6K-diphenylglucouril. The reaction
mixture was incubated for 10 min at room temper-
ature. Subsequently, the reaction mixture was eluted
with PBS on a Sephadex G-25 column (PD-10, Phar-
macia, Uppsala, Sweden) to separate labeled SOD
from free 131I. The protein-containing fractions
were pooled. The speci¢c activity of the preparation
was adjusted to 1 mCi/mg by adding non-labeled
SOD to the 131I-labeled product. The labeling e⁄-
ciency was approx. 30%. The radiochemical purity
of the 131I-SOD was determined by instant thin-layer
chromatography (ITLC) on Gelman ITLC-SG strips
(Gelman Laboratories, Ann Arbor, MI, USA) with
0.15 M citrate bu¡er pH 5.0 as the mobile phase.




Multilamellar liposomes were prepared by the de-
hydration-rehydration method followed by extrusion
as previously described [18]. Brie£y, mixtures of the
appropriate amounts of lipids in chloroform were
dried under a nitrogen stream until a homogeneous
¢lm was formed. This ¢lm was dispersed (32 or
16 Wmol lipid per ml hydration medium) in a solu-
tion of SOD in 6 mM DTPA (0.5, 2.0 or 5 mg/ml),
frozen in liquid nitrogen and lyophilized overnight.
Then, bu¡er (0.28 M mannitol/10 mM citrate bu¡er
pH 5.6) was added to the lyophilized powder in a
volume amounting to 1/10 of the volume of the orig-
inal dispersion. This hydration step lasted 30 min,
and, subsequently, 0.145 M NaCl/10 mM citrate
bu¡er pH 5.6 was added to adjust the ¢nal volume to
the starting volume. After 30 min, liposomes were
extruded sequentially through polycarbonate ¢lters
ranging from 0.6 to 0.2 Wm or 0.05 Wm in pore
size. Non-encapsulated protein was separated from
the liposome dispersion by ultracentrifugation, at
300 000Ug for 120 min at 4‡C in a Beckman LM-
80 ultracentrifuge. Finally, liposomes were dispersed
in 0.145 M NaCl/10 mM citrate bu¡er pH 5.6 in 1/5
of the initial volume. To remove the non-encapsu-
lated DTPA, liposomes were passed through an
Econo-PAC 10DG column (Bio-Rad).
111In labeling: preformed SOD-liposomes contain-
ing DTPA were labeled with 111In, which was trans-
ported through the bilayer in the form of 111In-oxine
and trapped irreversibly in the internal aqueous
phase, due to the chelation by intraliposomal
DTPA. Brie£y, 0.3 mCi (1.4 ml) of 111In-oxine in
0.5 M Tris-HCl, pH 7.0 was added to 2.0 ml of
each liposomal preparation (20 Wmol total lipid/ml)
and incubated for 1 h. The non-encapsulated 111In-
oxine was removed by gel ¢ltration on a Econo-PAC
10DG column. The encapsulation e⁄ciency of the
remote labeling procedure was always higher than
85%.
2.4.2. 131I-SOD liposomes
Multilamellar liposomes were prepared by the de-
hydration-rehydration method followed by extrusion
as described above, but with the following changes: (1)
the lipid ¢lm was dispersed in a solution of 131I-SOD
(0.5^1 mg/ml, 1 mCi/mg), and (2) non-encapsulated
protein was removed by gel ¢ltration on a Sephadex
G-200 column (18 cmU1 cm) and eluted with 0.145 M
NaCl/10 mM citrate bu¡er pH 5.6.
2.5. Liposome characterization
Mean liposome size was determined by dynamic
light scattering with a Malvern 4700 system. As
measure of particle size distribution the polydisper-
sity index (PI) was used. PI can range from 0 (mono-
disperse) to 1.0 (polydisperse).
Phospholipid concentration was determined ac-
cording to Fiske and Subbarow [30] as modi¢ed by
King [31].
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2.6. Animal experiments
2.6.1. Induction of the in£ammation
Wistar rats were injected with a single intradermal
injection of 0.10^0.15 ml of a suspension of Myco-
bacterium butiricum killed and dried (Difco) in in-
complete Freund’s adjuvant at 10 mg/ml, into the
subplantar area of the right hind paw [18]. The pa-
rameter of interest of adjuvant-induced arthritis is
the swelling of the paw which typically is established
after day 7 post induction.
2.6.2. Imaging protocol
Seven days after the induction of the in£amma-
tion, the various liposomal preparations under inves-
tigation were injected i.v., three rats per group (di-
vided randomly). Rats were anesthetized (halothane/
nitrous oxide/oxygen) and placed prone on a single-
head Q-camera equipped with a parallel-hole medium
(111In)- or high (131I)-energy collimator (Orbiter, Sie-
mens, Ho¡mann Estates, IL, USA). The groups of
rats were imaged synchronously at selected time
points after injection. The scintigraphic results were
analyzed by drawing regions of interest over the
heart region and over the whole animal.
2.6.3. Biodistribution protocol
To study the biodistribution of the radiolabeled
liposomes, groups of ¢ve rats each were injected
i.v. 7 days after induction of in£ammation with a
single dose (10 Wmol total lipid) of the di¡erent lip-
osomal preparations. 24 h or 48 h post injection rats
were killed by intraperitoneal injection of 30 mg phe-
nobarbital. Blood was obtained by cardiac puncture.
Following cervical dislocation, di¡erent organs and
tissues (in£amed foot (foot+), non-in£amed contrala-
teral normal foot (foot3), liver, spleen, blood, lung,
kidney and muscle) were dissected, weighed and as-
sayed for radioactivity in a shielded well-type Q-coun-
ter.
2.7. Statistical analysis
Results are presented as mean þ standard deviation
(S.D.). Statistical analysis was performed using the
ANOVA test.
3. Results
3.1. In vivo fate of the liposomal carrier: liposomes
labeled with 111In-DTPA
To study the in vivo behavior of SOD-liposomes
in rats with a chronic arthritic in£ammation, the
SOD-liposomes were labeled by the coencapsulation
of the complex 111In-DTPA in the aqueous internal
space of the liposomes. This complex is a high a⁄n-
ity complex at physiological pH [32] and has a very
short half-life due to e⁄cient renal excretion when
present as free complex in the blood circulation (half-
life in the order of minutes) [33]. These character-
istics make the 111In-DTPA complex an appropriate
label to monitor the in vivo fate of liposomes after
i.v. injection.
The in vivo fate of three di¡erent SOD-liposome
types was studied in a rat adjuvant arthritis model.
Major liposome characteristics are shown in Table 1.
Two PEG-liposome formulations di¡ering in size
(mean sizes of 110 nm and 200 nm) were studied
and compared with a SOD-liposome containing
SA. The latter formulation containing SA (further
referred to as SA-liposomes) was included in
this study as it has been shown earlier [18] to have
antiarthritic activity in this model. All three SOD-
liposome dispersions had similar SOD loading char-
Table 1
Characteristics of 111In-labeled SOD-liposomes studied in vivo
Lipid composition Molar ratio EE (%) Mean size (Wm) PI
110 nm PEG-liposomes E-PC:Chol:DSPE-PEG 1.85:1:0.15 7 0.11 þ 0.06 6 0.13
200 nm PEG-liposomes E-PC:Chol:DSPE-PEG 1.85:1:0.15 20 0.20 þ 0.02 6 0.24
SA-liposomes E-PC:Chol:SA 7:2:1 30 0.21 þ 0.03 6 0.23
All formulations contained 12^15 Wg of SOD per Wmol of total lipid.
EE, initial protein/lipid ratio divided by ¢nal protein/lipid ratio.
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acteristics as re£ected by similar protein-to-lipid ra-
tios.
3.1.1. Imaging studies
Whole body images obtained at di¡erent time
points post injection of the three SOD liposomal
formulations are shown in Fig. 1. The arthritic area
was visualized with each of the three liposome types.
The uptake in the in£amed foot was clearly higher
for the 110 nm PEG-SOD-liposomes as compared to
the other two liposome types (200 nm PEG-liposo-
mess SA-liposomes). In addition, uptake by the liv-
er, spleen and kidneys was observed. The whole-body
retention of radiolabel derived from quantitative
analysis of the images is shown in Fig. 2. At 46 h
post injection, label excretion amounted to approx.
35% in case of the SA-liposomes and approx. 20% in
case of both PEG-liposome types.
Fig. 3 shows heart activity data derived from
quantitative analysis of the images. The activity in
the heart region represents the activity in the blood
pool. The three SOD-liposome types under study ex-
hibit bicompartmental behavior regarding blood
Fig. 1. Scintigrams of rats with adjuvant arthritis imaged at selected time points post injection for: (A) 110 nm PEG-liposomes, (B)
200 nm PEG-liposomes and (C) SA-liposomes, labeled with 111In-DTPA.
Fig. 2. Whole-body activity pro¢les derived from quantitative
analysis of scintigraphic images of rats with adjuvant arthritis
(three rats per group), injected with 111In-DTPA-labeled lipo-
somes: 110 nm PEG-liposomes (b), 200 nm PEG-liposomes
(F), and SA-liposomes (R). The whole-body activity at 5 min
post injection was set at 100% ID. Values are mean þ S.D.
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clearance. The smaller sized PEG-liposomes (110 nm
PEG-liposomes) showed longer residence time in the
blood compartment as compared to the other two
formulations studied: at the end of the observation
period (46 h post injection) 23 þ 5% of the injected
dose (ID) was still present in the circulation, while
values of 7 þ 1% and 3 þ 1% were observed for
200 nm PEG-liposomes and 200 nm SA-liposomes,
respectively.
3.1.2. Biodistribution studies
The biodistribution data obtained at 24 h post
injection are shown in Fig. 4. These data clearly in-
dicate that the spleen is the main organ of accumu-
lation. Splenic uptake in terms of the percentage of
the injected dose per gram of tissue (ID/g) was high-
est for the 200 nm PEG-liposomes formulation:
mean uptake amounted to 37 þ 10% ID/g, indicating
that almost 20% of the injected dose accumulated in
the spleen. At the 24 h observation time point,
splenic uptake values for the 110 nm PEG-liposomes
and SA-liposomes were 19 þ 3% ID/g and 21 þ 7%
ID/g, respectively. The liver showed less pronounced
accumulation; hepatic uptake was highest for the
SA-liposomes: mean uptake amounted to
1.6 þ 0.6% ID/g. Hepatic uptake values for the
200 nm PEG-liposomes and 110 nm PEG-liposomes
were 0.9 þ 0.2% ID/g and 0.6 þ 0.2% ID/g, respec-
tively. The blood levels were highest for the 110 nm
PEG-liposomes (1.3 þ 0.5% ID/g), followed by the
200 nm PEG-liposomes (0.6 þ 0.1% ID/g) and SA-
liposomes (0.05 þ 0.05% ID/g). The three SOD-lipo-
some types also showed signi¢cant di¡erences in up-
take by the in£amed foot (foot+, Fig. 4). The highest
uptake was seen with the 110 nm PEG-liposomes
(0.6 þ 0.2% ID/g), while uptake of the 200 nm
PEG-liposomes and uptake of the SA-liposomes
were signi¢cantly lower (0.3 þ 0.1% ID/g and
Fig. 3. Heart activity pro¢les derived from quantitative analysis
of scintigraphic images of rats with adjuvant arthritis (three
rats per group), injected with 111In-DTPA-labeled liposomes:
110 nm PEG-liposomes (b), 200 nm PEG-liposomes (F) and
SA-liposomes (R). The heart activity at 5 min post injection
was set at 100% ID. Values are mean þ S.D.
Fig. 4. Biodistribution of 111In-DTPA-labeled liposomes: 110
nm PEG-liposomes (white), 200 nm PEG-liposomes (grey) and
SA-liposomes (hatched), in rats with adjuvant arthritis, 24 h
post injection (¢ve rats per group). Values are mean þ S.D. %
ID/g3% of the injected dose/g of tissue; foot+, in£amed foot;
foot3, non-in£amed foot.
Fig. 5. In£amed foot-to-non-in£amed foot ratio obtained with
110 nm PEG-liposomes, 200 nm PEG-liposomes, and SA-lipo-
somes, 24 h post injection. Values represent mean þ S.D., ¢ve
rats per group. *Signi¢cantly di¡erent from the other two ra-
tios.
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0.1 þ 0.1% ID/g, respectively). The in£amed foot-to-
non-in£amed foot ratios are shown in Fig. 5. The
ratios obtained with the PEG-liposomes were signi¢-
cantly higher than the ratio obtained with the SA-
liposome formulation (P6 0.05), with the highest ra-
tio (13 þ 6) obtained in case of the 110 nm PEG-lip-
osomes.
3.2. In vivo fate of the encapsulated drug: liposomes
labeled with 131I-SOD
To study the possible release of SOD from circu-
lating liposomes, the enzyme was labeled with 131I.
Characteristics of the PEG-liposomes and SA-lipo-
somes as well as the SOD, and lipid doses used in
the in vivo experiments are presented in Table 2.
3.2.1. Imaging studies
Fig. 6 shows the whole-body activity results de-
rived from quantitative analysis of the images. For
the free enzyme (131I-SOD), a rapid label excretion
up to 25% in the ¢rst minutes post injection was
observed. At 46 h post injection, the excreted amount
of the injected label dose was about 95%. In case of
injection of SOD-liposomes, label excretion during
the ¢rst 10 h post injection was much slower. How-
Table 2
Characteristics and injected doses of the 131I-SOD-liposomes studied in vivo








200 nm PEG-liposomes E-PC:Chol:DSPE-PEG 1.85:1:0.15 0.21 þ 0.01 20 133 11
SA-liposomes E-PC:Chol:SA 7:2:1 0.20 þ 0.01 25 66 8
SOD ^ ^ ^ ^ 75 ^
EE, initial protein/lipid ratio divided by ¢nal protein/lipid ratio.
Fig. 6. Whole-body activity pro¢les derived from quantitative
analysis of scintigraphic images of rats with adjuvant arthritis
(three rats per group), injected with 131I-labeled 200 nm PEG-
liposomes (F), 131I-labeled SA-liposomes (R) and 131I-SOD (b).
The whole-body activity at 5 min post injection was set at
100% ID. Values represent mean þ S.D.
Fig. 7. Heart activity pro¢les derived from quantitative analysis
of scintigraphic images of rats with adjuvant arthritis (three
rats per group), injected with 131I-labeled 200 nm PEG-lipo-
somes (F), 131I-labeled SA-liposomes (R) and 131I-SOD (b).
The heart activity at 5 min post injection was set at 100% ID.
Values represent mean þ S.D.
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ever, at 46 h post injection, label excretion was ex-
tensive and amounted to about 80% and 90% for 200
nm PEG-liposomes and SA-liposomes, respectively.
Comparison of the whole-body activity pro¢les ob-
tained with the 131I-SOD-liposomes (Fig. 6) and with
the 111In-labeled SOD-liposomes (Fig. 2) reveals a
much higher rate and extent of label excretion in
case of 131I-SOD-liposomes. Importantly, the blood
pool activity time course pro¢les shown in Fig. 3
(111In-labeled SOD-liposomes) and Fig. 7 (131I-
SOD-liposomes) are similar which indicates that the
majority of encapsulated SOD is not released from
the circulating SOD-liposomes within the blood
stream. Free 131I-SOD was rapidly cleared; only
20% of the injected dose was in the blood compart-
ment at 20 min after injection (Fig. 7).
3.2.2. Biodistribution studies
The 48 h biodistribution data are summarized in
Fig. 8. Strikingly, the 131I levels observed in all tis-
sues studied were very low as compared with the
111In levels shown in Fig. 4. For the free enzyme,
the main organ of accumulation was the kidney
with an uptake of 1.4 þ 0.7% ID/g. Label recovery
from all the other organs studied was very low (in
all tissues less than 0.05% ID/g). In case of the two
131I-labeled SOD-liposome types, the highest uptake
was observed in the spleen. The second organ of
uptake was the kidney, likely re£ecting label excre-
tion. Label accumulation in all other tissues studied
(including the in£amed foot) was low (6 0.2% ID/g).
4. Discussion
In any study dealing with the monitoring of the in
vivo fate of liposomes, the selection of reliable radio-
labels should be based on considerations relating to
the objectives of the study, the physico-chemical na-
ture of the liposomes, and the physico-chemical na-
ture of the molecules to be incorporated [34]. The
molecule of interest in this study, SOD, is a water
soluble enzyme. Accordingly, we have chosen a water
soluble complex (111In-DTPA) which was co-encap-
sulated in the internal aqueous space of the lipo-
somes. The In-111 radionuclide is an appropriate
label as it emits Q-radiation of a suitable energy
and its physical half-life of 67 h allows monitoring
of the in vivo fate of liposomes during long periods
of time after administration [32]. When 111In-DTPA
is released from liposomes circulating in the blood, it
is rapidly cleared from the circulation and leaves the
body through renal excretion [33]. When the 111In-
DTPA complex is released from the liposomes in
tissues other than blood, the liberated label remains
associated with the site, primarily due to transloca-
tion of radiolabel to iron-binding proteins [35^37].
Consequently, the 111In label can only accumulate
in tissues for long periods of time after being deliv-
ered via liposomes [38]. Therefore, we consider that
111In-DTPA is an appropriate label to study the dis-
position of liposomes in vivo.
After i.v. administration of various 111In-labeled
SOD-liposome types, a small degree of leakage of
the radiolabel in the blood circulation was observed
(Fig. 2). For the formulations studied, the lipid com-
position seems to be more important than the lip-
osome size in terms of whole body excretion (Fig.
2). Liposomes coated with PEG showed less leakage
and therefore less label excretion than the SA-lipo-
somes, suggesting a protective e¡ect of the PEG
coating against plasma protein-mediated leakage.
At 24 h post injection, the blood levels of 110 nm
and 200 nm PEG-liposomes were 8- and 3-fold high-
er, respectively, as compared with the SA-liposomes
lacking PEG (Fig. 3). In addition to the PEG coat-
ing, size appears to be an important factor in£uenc-
Fig. 8. Biodistribution of 131I-labeled 110 nm PEG-liposomes
(white), 131I-labeled SA-liposomes (grey) and 131I-SOD
(hatched), in rats with adjuvant arthritis, 48 h post infection
(¢ve rats per group). Values are mean þ S.D. % ID/g3% of the
injected dose/g of tissue; foot+, in£amed foot; foot3, non-in-
£amed foot.
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ing the circulation time of PEG-liposomes as the
larger 200 nm PEG-liposomes were cleared more
rapidly than the 110 nm PEG-liposomes (Fig. 3).
Thus, the presence of a PEG coating as well as a
small size are favorable factors for achieving long
circulation half-lives of SOD-liposomes, which is in
line with other literature reports [20,21,24,25,27].
The biodistribution data show that the spleen is
the main organ of uptake for the three SOD-lipo-
some types under investigation. The splenic uptake
of the 200 nm PEG coated SOD-liposomes was
about 2-fold higher than the uptake of the smaller
sized 110 nm PEG-liposomes. The markedly high
splenic uptake of the 200 nm PEG-liposomes has
been shown to be likely due to physical ¢ltration
rather than phagocytosis by spleen macrophages
[22,25,39]. Using £uorescent microscopy, it was dem-
onstrated that larger PEG-liposomes localize in the
red pulp and marginal zone without being internal-
ized by macrophages [40].
The present study shows that PEG-liposomes, in
particular small-sized ones, are to be preferred over
SA-liposomes for the targeting of SOD to the ar-
thritic lesions in rats with adjuvant arthritis (Figs. 4
and 5). Most probably, the longer residence time of
the PEG-liposomes in the bloodstream explains why
localization of the PEG-liposomes in the in£amed
area is higher than the localization of the SA-lipo-
somes: the persistently higher blood concentrations
of PEG-liposomes facilitate the continued extravasa-
tion of the PEG-liposomes at the in£ammatory fo-
cus.
The mechanisms of retention of liposomes in the
in£ammatory lesion remain to be elucidated. The
increased blood volume in the in£amed foot can
only partly explain the enhanced uptake of PEG-lip-
osomes in in£amed foot, as the 111In levels at the
arthritic site increase as a function of time (Fig. 1)
while the 111In levels in the blood decrease in time.
Obviously, successful targeting of SOD to sites of
arthritis can only be achieved when the liposomal
SOD contents is not lost during transport in the
bloodstream. From the present study, it can be con-
cluded that the majority of SOD administered in lip-
osomal form remains within the liposomes when they
circulate in the bloodstream. This conclusion is based
on the similar blood pool activity pro¢les obtained in
case of the 111In-labeled liposomes (Fig. 3) and the
131I-SOD liposomes (Fig. 7). In contrast, however, it
should be noted that 131I levels in tissues (Fig. 8)
were much lower than 111In levels in tissues (Fig.
4). A possible explanation for the lower levels of
the 131I label in tissues is the dehalogenation of the
protein after release from liposomes, possibly medi-
ated by the presence of multiple deiodinases in many
tissues [41]. The use of oxidants, such as iodogen for
the direct radioiodination of proteins, results primar-
ily in the formation of iodinated tyrosine residues.
Proteins labeled by this approach have been observed
to undergo extensive loss of label in vivo presumably
due to recognition of these iodoresidues by the de-
iodinases [42]. This explanation for the much lower
tissue accumulation of the 131I label is supported by
the higher degree of whole body excretion (Figs. 2
and 6) of the 131I label as compared to the 111In
label.
In conclusion, this study shows the superiority of
small-sized PEG-liposomes for the targeting of SOD
to in£amed sites. The present data warrant our hope
that PEG-liposomes may become e¡ective vehicles
for the treatment of rheumatoid arthritis.
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